Today, People suffering from diastolic heart failure have a cause to smile thanks to the new device created by doctors at Haifa’s Rambam Health Care Campus, Israel. To make things better, the new device has been successfully implanted in a patient with diastolic heart failure. Medical professionals in the hospital implanted the device in Robert MacLachlan, a 72-year-old patient who has run out of treatment options in his home country.

For the most part, CORolla is an elastic device designed by CorAssist Cardiovascular, a startup headquartered in Haifa, Israel. The device is meant to assist the left ventricle to open up to a greater volume during the diastolic filling — period when the heart relaxes and gets filled with blood before being ejected. The CORolla device is actually a structure that’s made of metal wire which includes a set of springs that work in tandem to push outward after being compressed by the left ventricle.

This device, created by Dr. Yair Feld, Dr. Yotam Reisner and Dr. Shay Dubi of Rambam improves the function of the heart by putting pressure on the ventricle so the heart can be filled with blood. CORolla is implanted in the left ventricle via a transapical approach which happens to be less invasive procedure compared to open heart surgery.

Professor Rafi Beyer, director and CEO of Rambam says, “Patients turns to us for the Rabnam advantage.” He also added, “They know that Rabnam’s physician researchers have access to some of the most innovative technologies and treatments.” “I am proud that Rambam offers treatments to patients not available anywhere else in the world,” he said.

Since the device has been successfully implanted in the first patient, the Ministry of health in Israel authorized up to 10 clinical trials of the device at the hospital to test the effectiveness of the treatment.

It’s important to note that about forty percent of patients suffering from heart failure are likely to die within five years. That being said, we can conclude that this new Israeli device will be able to make a difference and benefit up to 23 million people around the world who suffer from the life-threatening disease.